{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:37:03Z","timestamp":1790890623210,"version":"4.1.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,10,1]]},"abstract":"<jats:p>Idiopathic anaphylaxis remains a perplexing disorder in which existing prophylactic therapy is inadequate. In this prospective study, we sought to determine whether patients with idiopathic anaphylaxis might have evidence for a clonal disorder of mast cells related to mastocytosis and for which novel targeted therapies might be considered. We report 12 patients with \u201cidiopathic\u201d anaphylaxis who did not exhibit either urticaria pigmentosa or the characteristic bone marrow biopsy finding of multifocal mast-cell aggregates observed in systemic mastocytosis. Of these 12 patients, 5 had evidence of 1 or more minor criteria for mastocytosis. C-KIT mutational analysis was positive for the 816D&gt;V activating mutation in 3 of 3 patients in CD25+ bone marrow cells where the analysis was performed. These results demonstrate the presence of an aberrant mast-cell population carrying clonal markers in a subset of patients diagnosed with \u201cidiopathic\u201d anaphylaxis, who may respond to inhibitors targeting mutated C-KIT. This intramural clinical trial was conducted in 2003 and 2004 and was registered at http:\/\/clinicalcenter.nih.gov with a study number 03-I-0010. Since the study is now closed, it is no longer available online.<\/jats:p>","DOI":"10.1182\/blood-2006-06-028100","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T00:41:30Z","timestamp":1184632890000},"page":"2331-2333","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":207,"title":["Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis"],"prefix":"10.1182","volume":"110","author":[{"given":"Cem","family":"Akin","sequence":"first","affiliation":[{"name":"Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD;"},{"name":"Division of Allergy and Immunology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Scott","sequence":"additional","affiliation":[{"name":"Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can N.","family":"Kocabas","sequence":"additional","affiliation":[{"name":"Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Kushnir-Sukhov","sequence":"additional","affiliation":[{"name":"Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Brittain","sequence":"additional","affiliation":[{"name":"Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Noel","sequence":"additional","affiliation":[{"name":"The Clinical Center, NIH, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111816474772900_B1","first-page":"1497","article-title":"Anaphylaxis and anaphylactoid reactions.","volume-title":"Middleton's Allergy Principles and Practice","author":"Lieberman","year":"2003","edition":"6th ed"},{"key":"2019111816474772900_B2","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(02)08908-0","article-title":"Systemic mastocytosis and recurrent anaphylactic shock.","volume":"359","author":"Koide","year":"2002","journal-title":"Lancet"},{"key":"2019111816474772900_B3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000083954","article-title":"Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes.","volume":"136","author":"Florian","year":"2005","journal-title":"Int Arch Allergy Immunol"},{"key":"2019111816474772900_B4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis.","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"key":"2019111816474772900_B5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00277-002-0575-z","article-title":"Mastocytosis: current concepts in diagnosis and treatment.","volume":"81","author":"Escribano","year":"2002","journal-title":"Ann Hematol"},{"key":"2019111816474772900_B6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal.","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"2019111816474772900_B7","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/00000478-199809000-00013","article-title":"Diagnostic value of immunostaining for tryptase in patients with mastocytosis.","volume":"22","author":"Horny","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"2019111816474772900_B8","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood.V91.8.2731.2731_2731_2736","article-title":"Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications.","volume":"91","author":"Escribano","year":"1998","journal-title":"Blood"},{"key":"2019111816474772900_B9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0145-2126(01)00050-9","article-title":"Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis.","volume":"25","author":"Escribano","year":"2001","journal-title":"Leuk Res"},{"key":"2019111816474772900_B10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0301-472X(99)00145-9","article-title":"Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis.","volume":"28","author":"Akin","year":"2000","journal-title":"Exp Hematol"},{"key":"2019111816474772900_B11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2353\/jmoldx.2006.060022","article-title":"Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.","volume":"8","author":"Akin","year":"2006","journal-title":"J Mol Diagn"},{"key":"2019111816474772900_B12","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-Kit mutation and response to imatinib.","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"2019111816474772900_B13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1084-8592(97)80032-X","article-title":"Optimization of the isolation and amplification of RNA from formalin-fixed, paraffin embedded tissue; the Armed Forces Institute of Pathology experience and lietarture review.","volume":"2","author":"Krafft","year":"1997","journal-title":"Mol Diagn"},{"key":"2019111816474772900_B14","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"2019111816474772900_B15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000096442","article-title":"Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome.","volume":"142","author":"Sonneck","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"2019111816474772900_B16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0145-2126(01)00020-0","article-title":"Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders.","volume":"25","author":"Schwartz","year":"2001","journal-title":"Leuk Res"},{"key":"2019111816474772900_B17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1074-7613(01)00159-5","article-title":"Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival.","volume":"14","author":"Kalesnikoff","year":"2001","journal-title":"Immunity"},{"key":"2019111816474772900_B18","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2002-10-3176","article-title":"IgE alone stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE + antigen but distinct from those used by Steel factor.","volume":"102","author":"Lam","year":"2003","journal-title":"Blood"},{"key":"2019111816474772900_B19","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.4049\/jimmunol.172.7.4048","article-title":"Monomeric IgE stimulates NFAT translocation into the nucleus, a rise in cytosol Ca2+, degranulation, and membrane ruffling in the cultured rat basophilic leukemia-2H3 mast cell line.","volume":"172","author":"Pandey","year":"2004","journal-title":"J Immunol"},{"key":"2019111816474772900_B20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood-2003-08-2769","article-title":"NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation.","volume":"104","author":"Tkaczyk","year":"2004","journal-title":"Blood"},{"key":"2019111816474772900_B21","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood-2004-02-0631","article-title":"Kit and Fc\u03f5RI mediate unique and convergent signals for release of inflammatory mediators from human mast cells.","volume":"104","author":"Hundley","year":"2004","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/7\/2331\/483287\/zh801907002331.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/7\/2331\/483287\/zh801907002331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T21:47:59Z","timestamp":1574113679000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/7\/2331\/103573\/Demonstration-of-an-aberrant-mastcell-population"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,1]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,10,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2006-06-028100","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,1]]}}}